Scientists at Jnana aren’t the only ones with such high hopes for SLCs. Giulio Superti-Furga, a researcher at Medical University of Vienna, also sees SLCs as one of the next major drug discovery ...

Jnana Therapeutics Inc. is launching with $50 million and a plan to discover drugs for cancer and other conditions by zeroing in on cellular proteins.

Jnana’s lead program, JNT-517, is in development for phenylketonuria (PKU), an inherited disorder that leads to deficiency of an enzyme needed to break down phenylalanine, an amino acid found in ...

Jnana launched in 2017 with $50 million to build a platform that would enable the systematic discovery of drugs targeting SLCs. Although there are more than 400 proteins in this family, only 20 of ...

BOSTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Headquartered in Boston, Massachusetts, Jnana Therapeutics Inc. was launched in 2017 with $50 million in Series A financing from investors including Polaris Partners, Avalon Ventures, Versant ...

Jnana’s wholly owned lead program, JNT-517, which targets an allosteric site on the phenylalanine transporter SLC6A19, is a potential first-in-class oral approach for the treatment of ...

BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to ...

BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Biotech Jnana tops up with $107M series C, $2B Roche deal as it pushes metabolic asset into clinic By Max Bayer Nov 15, 2022 6:00am Jnana Therapeutics series C Roche Food and Drug Administration (FDA) ...

Jnana should be developed through a deep study of Atma Jnana Sastras and association with the wise and the performance of virtuous actions without any expectation of fruits. This Subheccha or good ...

Jnana is approaching completion of its Phase 1a study of JNT-517, which was initiated in Australia in late 2022 in healthy volunteers. JNT-517 is the first in a pipeline of potential therapies ...